About Doptelet®

 

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease before a scheduled procedure

CONFRONT THE RISKS OF BLEEDING HEAD ON WITH DOPTELET

ABOUT DOPTELET® (avatrombopag)

In 2 randomized, double-blind, placebo-controlled studies (N=435)1:

DOPTELET® (avatrombopag) works with the body to increase platelet counts1

DOPTELET provides added protection during and after the procedure1

DOPTELET provides added protection during and after the procedure

*From randomization of DOPTELET 40 mg or DOPTELET 60 mg once daily for 5 days up to 7 days after a procedure, compared to placebo (P<.001; N=435).1

On procedure day, 10 to 13 days after starting DOPTELET 40 mg or DOPTELET 60 mg once daily for 5 days, compared to placebo (P<.0001; N=435).1

In pooled analysis of ADAPT-1 and ADAPT-2 (N=251).2

DOPTELET® (avatrombopag) IS AN ORAL TREATMENT THAT HELPS PATIENTS PRODUCE MORE OF THEIR OWN PLATELETS1

View the DOPTELET Mechanism of Action

References:

1. DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc.

2. Data on file. Dova Pharmaceuticals, Inc.

Dova® 1Source™

Committed to helping patients navigate access to their prescribed therapy

Dova 1Source can help your prescribed patients navigate access at any point through the fulfillment process.

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

IMPORTANT SAFETY INFORMATION FOR DOPTELET

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. In the ADAPT-1 and ADAPT-2 clinical trials, there was 1 treatment-emergent event of portal vein thrombosis in a patient (n=1/430) with chronic liver disease and thrombocytopenia treated with DOPTELET. Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).

DOPTELET should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.

Contraindications: None

Adverse Reactions

The most common adverse reactions (≥3%) were: pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral.

 

Please see Full Prescribing Information for DOPTELET® (avatrombopag).

Visit Dova.com for WAC pricing.

 
 

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

IMPORTANT SAFETY INFORMATION FOR DOPTELET

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. In the ADAPT-1 and ADAPT-2 clinical trials, there was 1 treatment-emergent event of portal vein thrombosis in a patient (n=1/430) with chronic liver disease and thrombocytopenia treated with DOPTELET. Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).